Every new development in aging science, biohacking and new therapies, found as it happens, read at the original source and labeled by how strong the evidence is. We don’t tell you what works. We show you what was found.
In a six-month study of 536 men, a slow-release pill version of minoxidil, the active ingredient in Rogaine, grew more hair than a dummy pill. The results come from the company and have not been independently checked yet.
In a six-month study of 536 men, a slow-release pill version of minoxidil, the active ingredient in Rogaine, grew more hair than a dummy pill. The results come from the company and have not been independently checked yet.
In a year-long study of 410 people with early Parkinson’s, the supplement nicotinamide riboside (NR) raised a molecule cells use for energy, but did not slow the disease. Symptoms got slightly worse than on a dummy pill.
Charalampos Tzoulis7 sources · 5 minNovo Nordisk and Eli Lilly told an aging conference that people taking semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) appeared to age more slowly on lab estimates of biological age. Nothing has been peer reviewed yet.
Three people with glaucoma had no serious side effects in the eight weeks after a single eye injection, and two showed some improvement in their field of vision, Life Biosciences said. It is a very early, company-reported result.
Roche's PrevenTRON study will give an experimental antibody or a placebo (a dummy treatment) to about 1,600 people aged 55 to 80 who have no memory problems but carry a blood marker linked to Alzheimer's.
In 42 people with a scarring lung disease, six separate blood-protein aging tests all read younger on an experimental AI-designed drug. The split dose gave the steadiest signal, and the result is not proof it slows aging.
Alex Zhavoronkov10 sources · 6 minuniQure has asked US and UK regulators to approve its one-time Huntington's gene therapy. The request rests on small early trials compared with untreated patients from outside the studies.
Try a shorter search or another topic.
The biology of aging and the research trying to slow or reverse it: reprogramming, senescence, aging clocks, animal lifespan studies.
Longevity and age-related therapies tested in people: what started, what read out, and what the numbers say.
New hair-loss treatments from lab to clinic, with the stage of evidence behind each one.
Human studies on popular longevity supplements and compounds, read for what they measured and in whom.
How AI is being used to find drugs, design proteins and measure biological age.
Therapies that change the outlook for a disease: gene therapies, cell therapies and first-of-their-kind results.
We scan journals, preprints, trial registries, regulators, company news and the people in the field every 6 hours.
Every story goes back to the paper, the registry record or the person’s own words, cross-checked with independent reporting.
A mouse study, a company claim and a randomized trial are not the same thing. Each story says which one it is.
We don’t tell you what works. We report what was measured, in whom, and what is still unknown.
David Sinclair
